DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

NCT03688178 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

BIOLOGICAL: Human CMV pp65-LAMP mRNA-pulsed autologous DCs
DRUG: Temozolomide
BIOLOGICAL: Varlilumab
BIOLOGICAL: Td
BIOLOGICAL: Unpulsed DCs

Sponsor

Annick Desjardins, MD

Collaborators

[object Object]